Novel compound heterozygous mutations of ATM in ataxia-telangiectasia: A case report and calculated prevalence in the Republic of Korea.
10.5734/JGM.2018.15.2.110
- Author:
Min Jeong JANG
1
;
Cha Gon LEE
;
Hyun Jung KIM
Author Information
1. Department of Pediatrics, Nowon Eulji Medical Center, Eulji University, Seoul, Korea. leechagon@eulji.ac.kr
- Publication Type:Case Report
- Keywords:
Spinocerebellar degenerations;
Ataxia telangiectasia;
High-throughput nucleotide sequencing;
Prevalence
- MeSH:
Ankle;
Ataxia;
Ataxia Telangiectasia*;
Child;
Child, Preschool;
Databases, Genetic;
Dysarthria;
Early Diagnosis;
Gait;
Heterozygote;
High-Throughput Nucleotide Sequencing;
Humans;
Insurance, Health;
Intellectual Disability;
Male;
Muscle Spasticity;
Neurodegenerative Diseases;
Prevalence*;
Republic of Korea*;
Spinocerebellar Degenerations
- From:Journal of Genetic Medicine
2018;15(2):110-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ataxia-telangiectasia (AT; OMIM 208900) is a rare autosomal recessive inherited progressive neurodegenerative disorder, with onset in early childhood. AT is caused by homozygous or compound heterozygous mutations in ATM (OMIM 607585) on chromosome 11q22. The average prevalence of the disease is estimated at 1 of 100,000 children worldwide. The prevalence of AT in the Republic of Korea is suggested to be extremely low, with only a few cases genetically confirmed thus far. Herein, we report a 5-year-old Korean boy with clinical features such as progressive gait and truncal ataxia, both ankle spasticity, dysarthria, and mild intellectual disability. The patient was identified as a compound heterozygote with two novel genetic variants: a paternally derived c.5288_5289insGA p.(Tyr1763*) nonsense variant and a maternally derived c.8363A>C p.(His2788Pro) missense variant, as revealed by next-generation sequencing and confirmed by Sanger sequencing. Based on claims data from the Health Insurance Review and Assessment Service Republic of Korea, we calculated the prevalence of AT in the Republic of Korea to be about 0.9 per million individuals, which is similar to the worldwide average. Therefore, we suggest that multi-gene panel sequencing including ATM should be considered early diagnosis.
